ArticleJHEP reports : innovation in hepatology2023
Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis.
Article in JHEP reports : innovation in hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Stereotactic body radiation therapy for hepatocellular carcinoma: 2026 expert consensus-based practical recommendation of the Korean Liver Cancer Association.Radiation oncology journal · 2026Article
- Comparative efficacy of stereotactic body radiotherapy and percutaneous radiofrequency ablation for oligometastatic liver disease-radiation oncologists' perspective and practice guideline.The British journal of radiology · 2026Review
- Hepatic Resection versus Stereotactic Body Radiation Therapy as Initial Local Treatment for BCLC Stage 0 Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.Liver cancer · 2026Article
- Combining External Beam Radiotherapy and Immunotherapy for the Treatment of Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2026Review
- Tumor shrinkage after simultaneous proton therapy for multiple hepatocellular carcinomas.Journal of radiation research · 2025Article
- Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases.Scientific reports · 2025Article
- Comparative analysis of clinical treatment outcomes: Breath-hold vs. free-breathing techniques in liver stereotactic body radiotherapy.Journal of medical imaging and radiation oncology · 2025Article
- Assessment of real-time US-CT/MR-guided percutaneous gold fiducial marker implementation in malignant hepatic tumors for stereotactic body radiation therapy.Journal of liver cancer · 2024Article
- Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?Current oncology (Toronto, Ont.) · 2024Review
- Current perspectives on radiotherapy in hepatocellular carcinoma management: a comprehensive review.Journal of liver cancer · 2024Article
- Do We Have a Winner? Advocating for SBRT in HCC Management.Clinical and translational radiation oncology · 2024Article
- Understanding survival comparisons in nonrandomized treatment comparisons for patients with early-stage HCC.Hepatology communications · 2024Article
- Postoperative adjuvant immunotherapy and molecular targeted therapy for patients of hepatocellular carcinoma with portal vein tumor thrombus after hepatectomy: a propensity score matching study.Frontiers in surgery · 2024Article
- Oligometastasis: Expansion of Curative Treatments in the Field of Oncology.Medicina (Kaunas, Lithuania) · 2023Review
- Local Treatment of Hepatocellular Carcinoma with Oligometastases: A Systematic Review and Meta-Analysis.Cancers · 2023Article
- Effects of stereotactic body radiotherapy for clinical outcomes of patients with liver metastasis and hepatocellular carcinoma: A retrospective study.Oncology letters · 2023Article
- Review
- The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms.Frontiers in immunology · 2023Review
- Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Radiofrequency ablation (RFA) and ablative external beam radiotherapy (ablative RT) are commonly used to treat small intrahepatic malignancies. We meta-analysed oncologic outcomes and systematically reviewed the clinical consideration of tumour location and size. Methods: PubMed, Medline, Embase, and Cochrane Library databases were searched on February 24, 2022. Studies comparing RFA and ablative RT, providing one of the endpoints (local control or survival), and encompassing ≥5 patients in each arm were included. Results: Twenty-one studies involving 4,638 patients were included. Regarding survival, the odds ratio (OR) was 1.204 ( Conclusions: Our study shows that ablative RT can yield oncologic outcomes similar to RFA, and suggests that it can be more effective for the treatment of tumours in locations where RFA is difficult to perform or for large-sized tumours. Systematic Review Registration: This study was registered with PROSPERO (Protocol No: CRD42022332997). Impact and implications: Radiofrequency ablation (RFA) and ablative radiotherapy (RT) are non-surgical modalities for the treatment of small intrahepatic malignancies. Ablative RT showed oncologic outcomes at least similar to those of RFA, and was more effective at specific locations (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.